ROA

CNB COMMUNITY BANCORP, INC. REPORTS FOURTH QUARTER 2021 RESULTS

Retrieved on: 
Friday, January 14, 2022 - 3:59pm

Earnings during the fourth quarter of 2021 totaled $2.2 million, a decrease of $136,000 from the $2.4 million earned during the three months ended December 31, 2020.

Key Points: 
  • Earnings during the fourth quarter of 2021 totaled $2.2 million, a decrease of $136,000 from the $2.4 million earned during the three months ended December 31, 2020.
  • Basic earnings per share decreased to $1.04 during the three months ended December 31, 2021, down $0.07 from $1.11 during the fourth quarter of 2020.
  • The annualized return on average equity (ROE) decreased to 10.63% for the current quarter, down from 13.27% for the fourth quarter of 2020.
  • Pre-tax, pre-provision income decreased approximately $1.3 million to $2.9 million in the fourth quarter of 2021, compared to $4.2 million in the fourth quarter of 2020.

Sberbank: Sber earned RUB1,237 trn in net profit for 2021 (X1.7), excluding the effect of subsequent events

Retrieved on: 
Friday, January 14, 2022 - 8:02am

SberBank releases Financial Highlights for 2021, excluding the effect of subsequent events (under RAS, non-consolidated)

Key Points: 
  • SberBank releases Financial Highlights for 2021, excluding the effect of subsequent events (under RAS, non-consolidated)
    The numbers are calculated in accordance with SberBank's internal methodology.
  • The effect of subsequent events is included in the numbers as of January 1, 2021 but excluded from the numbers as of January 1, 2022.
  • The Bank earned RUB1,237 trn in net profit for the year, excluding the effect of subsequent events.
  • As a result, net profit for the year 2021 exceeded RUB1.2 trn with ROE close to 25%."

Crazy Woman Creek Bancorp Reports Record Earnings for Fiscal Year 2021; Pays Annual Cash Dividend of $0.31 per Share

Retrieved on: 
Wednesday, January 12, 2022 - 9:00pm

This dividend is a testament to the strength of our core banking activities and financial performance of our franchise.

Key Points: 
  • This dividend is a testament to the strength of our core banking activities and financial performance of our franchise.
  • Crazy Woman Creek Bancorp, Inc. is the holding company for Buffalo Federal Bank, a Wyoming State Chartered community bank.
  • The shares of Crazy Woman Creek Bancorp, Inc. are traded on the OTCPink under the symbol CRZY.
  • Crazy Woman Creek Bancorp, Incorporated disclaims any intent or obligations to update such forward looking statements.

Open Lending signs 71 Financial Institutions to the Lenders Protection Program in 2021

Retrieved on: 
Monday, January 10, 2022 - 9:05pm

AUSTIN, Texas, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Open Lending Corporation (NASDAQ: LPRO) (Open Lending or the Company), a leading provider of lending enablement and risk analytics solutions to financial institutions, today announced that it signed 71 new accounts to the Lenders Protection program in 2021, 18 of which were signed since October 1, 2021.

Key Points: 
  • AUSTIN, Texas, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Open Lending Corporation (NASDAQ: LPRO) (Open Lending or the Company), a leading provider of lending enablement and risk analytics solutions to financial institutions, today announced that it signed 71 new accounts to the Lenders Protection program in 2021, 18 of which were signed since October 1, 2021.
  • Lenders Protection, Open Lendings flagship product, is a risk management program featuring default insurance coverage for near-prime and non-prime auto loans.
  • Lenders Protection allows auto lenders to model their specific overhead and funding costs and set a target ROA for their insured portfolio.
  • Open Lending (NASDAQ: LPRO) provides loan analytics, risk-based pricing, risk modeling, and default insurance to auto lenders throughout the United States.

Global Hematopoietic Progenitor Kinase 1 Inhibitors Report 2021 - Featuring Treadwell Therapeutics, BeiGene and Blueprint Medicines Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 5, 2022 - 1:21pm

The therapies under development are focused on novel approaches for Hematopoietic progenitor kinase 1 inhibitors.

Key Points: 
  • The therapies under development are focused on novel approaches for Hematopoietic progenitor kinase 1 inhibitors.
  • This segment of the Hematopoietic progenitor kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • Hematopoietic progenitor kinase 1 inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Hematopoietic progenitor kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Hematopoietic progenitor kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

John Lacca Joins Cenlar as Vice President, Executive Client Management

Retrieved on: 
Tuesday, January 4, 2022 - 2:30pm

Cenlar FSB, the nations leading mortgage loan subservicer and federally chartered wholesale bank, announced today that John Lacca, a 28-year veteran in the credit union space, has joined the company as Vice President, Executive Client Management.

Key Points: 
  • Cenlar FSB, the nations leading mortgage loan subservicer and federally chartered wholesale bank, announced today that John Lacca, a 28-year veteran in the credit union space, has joined the company as Vice President, Executive Client Management.
  • Before joining Cenlar, John held multiple roles at the Police and Fire Federal Credit Union (PFFCU).
  • His extensive knowledge of the credit union model and member experience will be valuable in strengthening relationships with existing credit union partners, said Matthew Detwiler, Senior Vice President, Client Relationship Management.
  • As the nations leading subservicer, Cenlar boasts a loyal and growing client base including banks, credit unions and mortgage bankers.

New research method from Filene offers credit unions custom insights against benchmarks

Retrieved on: 
Thursday, December 30, 2021 - 6:03pm

Credit unions employing these bundles correlated with a higher return on assets and higher net income more than credit unions who did not.

Key Points: 
  • Credit unions employing these bundles correlated with a higher return on assets and higher net income more than credit unions who did not.
  • This corresponds to a 4% response rate for the entire credit union system, representing approximately 25% of all credit union assets.
  • Generous support for the Center of Excellence for Diversity, Equity and Inclusion is provided by Advantis Credit Union, Alaska USA Federal Credit Union, Bethpage Federal Credit Union, Civic Federal Credit Union, Desert Financial Credit Union, Kinecta Federal Credit Union, LGFCU, SchoolsFirst Federal Credit Union, State Department Federal Credit Union, Suncoast Credit Union, UNFCU, University of Michigan Credit Union, UW Credit Union, and Visions Federal Credit Union.
  • About Filene: Filene Research Institute strengthens organizations through innovative research and incubation to improve consumer financial well-being.

2021 P38 Mitogen - Activated Protein (MAP) Kinase Inhibitors Pipeline Insight Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 30, 2021 - 4:06pm

The "P38 Mitogen - Activated Protein (MAP) Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "P38 Mitogen - Activated Protein (MAP) Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P38 mitogen-activated protein (MAP) kinase inhibitors pipeline landscape.
  • P38 mitogen-activated protein (MAP) kinase inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different P38 mitogen-activated protein (MAP) kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • P38 mitogen-activated protein (MAP) kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Enterprise Asset Management (EAM) Markets to 2030 - Rising Demand for EAM Integration & Deployment, Consulting, Training, and Monitoring & Upgradation Services - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021 - 3:32pm

The "Enterprise Asset Management Market Research Report - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enterprise Asset Management Market Research Report - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global enterprise asset management market 2030 value will likely be $21,471.3 million, growing from $5,682.1 million in 2020 at a 14.2% CAGR between 2020 and 2030.
  • This will majorly be because EAM helps in reducing operational and maintenance costs and increasing the return on assets (ROA).
  • The demand for EAM integration & deployment, consulting, training, and monitoring & upgradation services will rise fast in the coming years.

2021 Global Merkel Cell Carcinoma Pipeline Insight Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021 - 11:49am

The "Merkel Cell Carcinoma - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Merkel Cell Carcinoma - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape.
  • This segment of the Merkel Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.